Date recv'd:	
PR#:	
For RAPC Office Use Only	

# APPLICATION FOR REVIEW Human Research Schedule I or Schedule II Controlled Substances

# Research Advisory Panel of California

All applicable sections of the application must be completed within the form field provided. Please type or print legibly. Note that certain fields require supporting attachments. Incomplete fields or missing attachments will delay the application process.

# A. TITLE AND DESCRIPTION OF STUDY

Attach copy of study protocol.

	B.	PRIN	ICIPAL	INVEST	TIGATOR
--	----	------	--------	--------	---------

**MAILING ADDRESS:** 

Attach	copy	of	CV's	of	Principal	Investigator	&	Sub	Investigators.

NAME: INSTITUTION:

DIRECT CONTACT PHONE #:

## C. LOCATION WHERE STUDY WILL BE CONDUCTED

#### D. STUDY AND COMPARATOR DRUGS

List study and comparator drugs and dosages - attach monograph for each. Include placebo if applicable.

Study Drug	Dose Range(s)

### E. SOURCE OF STUDY DRUGS

#### F. PLAN FOR STORAGE AND ACCOUNTABILITY OF STUDY DRUGS

If pharmacy based - storage and accountability plan not required - provide name and location of pharmacy.

G	DI	VINED	NUMBER	OF	SHE	<b>IFCTS</b>
G.	FL	AININED	NOMBER	OΓ	JUD.	ノレしょう

- H. STUDY DURATION FOR EACH SUBJECT
- I. ANTICIPATED STUDY START-UP AND COMPLETION DATES
- J. SOURCE OF FUNDING

#### K. CONSENT

Attach copy of informed consent to be used with study; along with copy of the California Research Subjects Bill of Rights.

L. NAME AND ADDRESS OF IRB; IRB REVIEW STATUS

If IRB approval already procured; attach documentation.

- M. If Applicable **PROVISIONS FOR HANDLING OF MEDICAL EMERGENCIES**If study drug is being administered at an onsite research lab, office, clinic, or hospital setting, a description of provisions for handling any medical emergencies that might occur is required. Attach description.
- **N.** If Applicable **PROVISIONS FOR DISPENSING OF TAKE HOME STUDY MEDS** If study requires subjects to "take home" single or multiple doses of study meds, a description of provisions for the dispensing and labeling of these medications is required. Attach description. If pharmacy based dispensing and labeling description not required provide name and location of pharmacy.
- O. <u>ACKNOWLEDGMENTS & SIGNATURE OF PRINCIPAL INVESTIGATOR</u>
  As a final step in completing this application, Principal Investigator acknowledges that, upon receipt of Panel

approval, he/she will comply with all Panel requirements, including prompt reporting of study emergent study drug related SAE's, and presentation of the California Research Subjects Bill of Rights to each subject at onset of consenting process.

	Signature	Date
D:\Checklst\RAPCcov.wpd (Marcl	1 24, 2003)	